www.durystahcp.com Open in urlscan Pro
2606:4700:4400::ac40:910e  Public Scan

Form analysis
0 forms found in the DOM

Text Content

 * ORDER
 * REIMBURSEMENT
 * TRAINING
   
   

 * For U.S. Healthcare Professionals Only
 * Prescribing Information
 * Important Safety Information
 * Patient Site
 * Request a Rep

 * About DURYSTA®
   What Is Durysta®?Direct DeliveryPotential Patients
 * Clinical Overview
   EfficacySafety
 * Getting Started
   OrderReimbursementTrainingResources
 * FAQs



 * About DURYSTA®
   * What Is Durysta®?
   * Direct Delivery
   * Potential Patients
 * Clinical Overview
   * Efficacy
   * Safety
 * Getting Started
   * Order
   * Reimbursement
   * Training
   * Resources
 * FAQs
   Prescribing Information Important Safety Information Patient Site Request a
   Rep
   For U.S. Healthcare Professionals Only


EXTENDED IOP CONTROL


DISCOVER THE DURYSTA® DIFFERENCE:

 * A first-in-class, biodegradable, intracameral implant to reduce IOP in
   patients with OAG or OHT1
 * 24/7 drug release for several months1,2
 * Delivers drug within the eye to target tissues1,3


SEVERAL MONTHS OF IOP REDUCTION WITH 1 IMPLANT1

scroll
 * IOP=intraocular pressure; OAG=open angle glaucoma; OHT=ocular hypertension.
 * Actual DURYSTA® patient.


EXTENDED IOP CONTROL


SEVERAL MONTHS OF IOP REDUCTION WITH 1 IMPLANT1


DISCOVER THE DURYSTA® DIFFERENCE:

 * A first-in-class, biodegradable, intracameral implant to reduce IOP in
   patients with OAG or OHT1
 * 24/7 drug release for several months1,2
 * Delivers drug within the eye to target tissues1,3

scroll
 * IOP=intraocular pressure; OAG=open angle glaucoma; OHT=ocular hypertension.
 * Actual DURYSTA® patient.

A first-in-class, biodegradable, intracameral implant for IOP control
24/7 drug delivery for several months1,2

The implant The applicator
Not actual size.

A solid polymer matrix containing 10 mcg of bimatoprost1

Slowly biodegrades in the eye1

A tiny, biodegradable, intracameral implant1,2

Approximately 1 mm in length2

Preservative-free4

Sterile applicator designed for single use1,4

Preloaded with 1 DURYSTA® implant1

A 28-gauge needle2

Treatment with DURYSTA® is limited to a single administration per eye1

scroll


DURYSTA® IS DIRECTLY DELIVERED TO TARGET TISSUES IN THE ANTERIOR CHAMBER
ANGLE1,3

Following administration, the intracameral implant is intended to settle within
the inferior angle to deliver a sustained release of bimatoprost.1


Bimatoprost is believed to lower IOP in humans by increasing the outflow of
aqueous humor through both the trabecular meshwork (conventional) and the
uveoscleral routes (unconventional).1


Placement of the implant within the anterior chamber angle allows for close
proximity to the tissues involved in both of these outflow pathways, where it
delivers bimatoprost 24/7 for several months.1-3




MEET MONICA


A REAL GLAUCOMA PATIENT

After she was diagnosed with glaucoma, Monica started using eye drops to lower
her IOP. She had trouble administering them at times and often forgot to use
them. Later, her doctor suggested DURYSTA®.



IOP=intraocular pressure.
Actual DURYSTA® patient.

Not actual DURYSTA® patients.

OTHER PATIENTS LIKE MONICA
MAY BE READY FOR DURYSTA®




OTHER PATIENTS LIKE MONICA MAY BE READY FOR DURYSTA®


CONSIDER DURYSTA® FOR YOUR PATIENTS WHO MAY BE:

Not actual DURYSTA® patients.

BACK TO MONICA,
AN ACTUAL DURYSTA® PATIENT

POTENTIAL PATIENTS MAY SHARE OTHER IMPORTANT CHARACTERISTICS

 * They struggle when administering their drops
 * Open to interventional therapy
 * They lead active lives
 * Often forget their medication

SLT=selective laser trabeculoplasty.

Previous Next

Efficacy demonstrated in 2 clinical studies
Sustained IOP control, month after month1

ARTEMIS STUDY 1 ARTEMIS STUDY 2


CONSISTENT MEAN IOP REDUCTION OVER TIME1

DURYSTA® 10 mcg (N=198)2

Timolol 0.5% BID (N=198)2

Baseline at Hour 0: 24.6 mmHg

Baseline at Hour 0: 24.6 mmHg



Up to 33% mean IOP reduction from baseline1

DURYSTA® 10 mcg (N=198)2

Timolol 0.5% BID (N=198)2

Baseline at Hour 0: 24.6 mmHg

Baseline at Hour 0: 24.6 mmHg


Up to 33% mean IOP reduction from baseline1
Mean IOP (mmHg)

DURYSTA® 10 mcg (N=176)2

Timolol 0.5% BID (N=176)2

Baseline at Hour 0: 24.3 mmHg

Baseline at Hour 0: 24.5 mmHg



Up to 32% mean IOP reduction from baseline1

DURYSTA® 10 mcg (N=176)2

Timolol 0.5% BID (N=176)2

Baseline at Hour 0: 24.3 mmHg

Baseline at Hour 0: 24.5 mmHg


Up to 32% mean IOP reduction from baseline1
Mean IOP (mmHg)


STUDY DESIGN


A SAFETY PROFILE ESTABLISHED IN 2 CLINICAL STUDIES1


MOST COMMON ADVERSE REACTIONS

OCULAR

The most common ocular adverse reaction was conjunctival hyperemia, which
occurred in 27% of patients.1



Other common ocular adverse reactions reported in 5-10% of patients were foreign
body sensation, eye pain, photophobia, conjunctival hemorrhage, dry eye, eye
irritation, IOP increased, corneal endothelial cell loss, vision blurred, and
iritis.1



Ocular adverse reactions occurring in 1-5% of patients were anterior chamber
cell, lacrimation increased, corneal edema, aqueous humor leakage, iris
adhesions, ocular discomfort, corneal touch, iris hyperpigmentation, anterior
chamber flare, anterior chamber inflammation, and macular edema.1

NONOCULAR

The most common nonocular adverse event was headache, which was observed in 5%
of patients.1


YOU HAVE OPTIONS WHEN ORDERING DURYSTA®

FOR ORDERING


GO TO ALLERGAN DIRECT™

Choose to order online with Allergan Direct through the buy-and-bill process—or
acquire DURYSTA® through a specialty pharmacy. The videos below provide
introductions to each of these options.

ORDERING DURYSTA® ONLINE WITH ALLERGAN DIRECT

Allergan Direct offers a convenient experience with 24/7, on-demand flexibility.
This solution allows you to place orders, pay invoices, and more.

Before ordering, you'll need to set up an Allergan Direct account by calling:
1-833-DURYSTA (1-833-387-9782)


IMPORTANT

Call from 8 am to 8 pm ET

Have your practice contact information ready—including billing and shipping
addresses—and your state license number

In order to run a credit check, we will need your business tax ID, bank name,
account number, and contact information


IF YOU ALREADY HAVE AN ACCOUNT FOR ALLERGAN DIRECT, REMEMBER:

There is a minimum order quantity of 2

Orders arrive within 2 business days

New accounts receive an initial courtesy credit line of $20,000 while we process
your credit application



HOW TO ORDER THROUGH A SPECIALTY PHARMACY

The benefits verification process will determine if your patient's insurance
accommodates specialty pharmacy distribution

Allergan EyeCue® will then help coordinate the specialty pharmacy experience

The specialty pharmacy contacts the patient to verify information and collect
their copay

Next, your office receives DURYSTA® from the specialty pharmacy and properly
stores it

Finally, you administer DURYSTA® to the patient when needed





REIMBURSEMENT SUPPORT WITH ALLERGAN EYECUE®

FOR REIMBURSEMENT HELP


GO TO ALLERGAN EYECUE®

YOUR COMPLETE RESOURCE FOR DURYSTA® REIMBURSEMENT AND ACCESS


FOR YOUR DURYSTA® PATIENTS, THROUGH ALLERGAN EYECUE® YOU CAN:

Initiate a benefit verification

Request prior authorization support

Gain online access to case/patient management

Access information about billing, coding, and reimbursement support

Request specialty pharmacy enrollment

Request claims assistance and appeals support

Enroll in the DURYSTA® Savings Program—eligible commercially-insured patients
pay $0* for up to one implant per eye

Submit claims for reimbursement under the DURYSTA® Savings Program

Before you can begin taking advantage of this resource for ongoing DURYSTA®
support, an Allergan EyeCue® account is required. Details are available at the
Allergan EyeCue® site.

Offer valid only for commercially-insured patients with plans covering DURYSTA®;
patient out-of-pocket expense may vary. Offer not valid for patients receiving
reimbursement from Medicare, Medicaid, or any other federal, state, or
government-funded healthcare program. See Program Terms, Conditions, and
Eligibility Criteria here or visit www.durystasavingsprogram.com.





THE DURYSTA® PHYSICIAN TRAINING PORTAL

FOR ADMINISTRATION HELP


VISIT THE TRAINING PORTAL

DESIGNED TO INTRODUCE YOU TO THE IMPLANT DELIVERY DIRECTIONS FOR DURYSTA®


THE PHYSICIAN TRAINING PORTAL PROVIDES:

An overview of the drug delivery system and mechanism of action

A video series featuring Paul Singh, MD, with insights on patient selection,
patient discussion, and administration

Demonstrations of correct administration technique

Examples of typical implant behavior following administration

A guide through various troubleshooting scenarios

Downloadable resources and supplements from Cataract & Refractive Surgery Today

Physician Administration Guide

A complete reference for the DURYSTA® administration procedure

DOWNLOAD


Download materials and resources for your practice and your patients


FOR YOUR PRACTICE


ORDERING

HOW TO ORDER FLASHCARD

A handy reference to consult when ordering DURYSTA®

Download



REIMBURSEMENT

PATIENT ENROLLMENT FORM

Quickly enroll patients in Allergan EyeCue® to begin taking advantage of the
available resources

Download



 

BILLING AND CODING GUIDE

A brief overview of billing and coding information for DURYSTA®

Download




ADDITIONAL RESOURCES

Buy-and-Bill/Specialty Pharmacy Flashcard
DURYSTA® Savings Program Flashcard for Offices
Allergan EyeCue® Overview
DURYSTA® Savings Program
Reimbursement Request Form
DURYSTA® Procedure Consent Form
Sample CMS-1500 Form
Sample ASC CMS-1500 Form
Sample UB-04 Form




FOR YOUR PATIENTS

DURYSTA® IN-OFFICE PATIENT SCREENER

A tool to help identify patients who might be potential candidates for DURYSTA®

Download


DURYSTA® SAVINGS PROGRAM PATIENT FLASHCARD

All the information eligible patients need to enroll and begin saving on their
DURYSTA® prescription costs

Download




INDICATIONS AND USAGE

DURYSTA® (bimatoprost intracameral implant) is indicated for the reduction of
intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular
hypertension (OHT).


IMPORTANT SAFETY INFORMATION


CONTRAINDICATIONS

DURYSTA® is contraindicated in patients with: active or suspected ocular or
periocular infections; corneal endothelial cell dystrophy (e.g., Fuchs’
Dystrophy); prior corneal transplantation or endothelial cell transplants (e.g.,
Descemet’s Stripping Automated Endothelial Keratoplasty [DSAEK]); absent or
ruptured posterior lens capsule, due to the risk of implant migration into the
posterior segment; hypersensitivity to bimatoprost or to any other components of
the product.


WARNINGS AND PRECAUTIONS

The presence of DURYSTA® implants has been associated with corneal adverse
reactions and increased risk of corneal endothelial cell loss. Administration of
DURYSTA® should be limited to a single implant per eye without retreatment.
Caution should be used when prescribing DURYSTA® in patients with limited
corneal endothelial cell reserve.

DURYSTA® should be used with caution in patients with narrow iridocorneal angles
(Shaffer grade < 3) or anatomical obstruction (e.g., scarring) that may prohibit
settling in the inferior angle.

Macular edema, including cystoid macular edema, has been reported during
treatment with ophthalmic bimatoprost, including DURYSTA® intracameral implant.
DURYSTA® should be used with caution in aphakic patients, in pseudophakic
patients with a torn posterior lens capsule, or in patients with known risk
factors for macular edema.

Prostaglandin analogs, including DURYSTA®, have been reported to cause
intraocular inflammation. DURYSTA® should be used with caution in patients with
active intraocular inflammation (e.g., uveitis) because the inflammation may be
exacerbated.

Ophthalmic bimatoprost, including DURYSTA® intracameral implant, has been
reported to cause changes to pigmented tissues, such as increased pigmentation
of the iris. Pigmentation of the iris is likely to be permanent. Patients who
receive treatment should be informed of the possibility of increased
pigmentation. While treatment with DURYSTA® can be continued in patients who
develop noticeably increased iris pigmentation, these patients should be
examined regularly.

Intraocular surgical procedures and injections have been associated with
endophthalmitis. Proper aseptic technique must always be used with administering
DURYSTA®, and patients should be monitored following the administration.


ADVERSE REACTIONS

In controlled studies, the most common ocular adverse reaction reported by 27%
of patients was conjunctival hyperemia. Other common adverse reactions reported
in 5%-10% of patients were foreign body sensation, eye pain, photophobia,
conjunctival hemorrhage, dry eye, eye irritation, intraocular pressure
increased, corneal endothelial cell loss, vision blurred, iritis, and headache.

Please see full Prescribing Information.

References: 1. DURYSTA® [Prescribing Information]. Irvine, CA: Allergan, Inc.;
2020. 2. Data on file, Allergan, 2020. 3. Standring S. Orbit and accessory
visual apparatus. In: Gray’s Anatomy: The Anatomical Basis of Clinical Practice.
41st ed. Philadelphia, PA: Elsevier Limited; 2016:666-708. 4. DURYSTA® NDA FDA
Approval Letter. March 4, 2020.


IMPORTANT SAFETY INFORMATION AND INDICATIONS AND USAGE
COLLAPSE


CONTRAINDICATIONS

DURYSTA® is contraindicated in patients with: active or suspected ocular or
periocular infections; corneal endothelial cell dystrophy (e.g., Fuchs’
Dystrophy); prior corneal transplantation or endothelial cell transplants (e.g.,
Descemet’s Stripping Automated Endothelial Keratoplasty [DSAEK]); absent or
ruptured posterior lens capsule, due to the risk of implant migration into the
posterior segment; hypersensitivity to bimatoprost or to any other components of
the product.


WARNINGS AND PRECAUTIONS

The presence of DURYSTA® implants has been associated with corneal adverse
reactions and increased risk of corneal endothelial cell loss. Administration of
DURYSTA® should be limited to a single implant per eye without retreatment.
Caution should be used when prescribing DURYSTA® in patients with limited
corneal endothelial cell reserve.

DURYSTA® should be used with caution in patients with narrow iridocorneal angles
(Shaffer grade < 3) or anatomical obstruction (e.g., scarring) that may prohibit
settling in the inferior angle.

Macular edema, including cystoid macular edema, has been reported during
treatment with ophthalmic bimatoprost, including DURYSTA® intracameral implant.
DURYSTA® should be used with caution in aphakic patients, in pseudophakic
patients with a torn posterior lens capsule, or in patients with known risk
factors for macular edema.

Prostaglandin analogs, including DURYSTA®, have been reported to cause
intraocular inflammation. DURYSTA® should be used with caution in patients with
active intraocular inflammation (e.g., uveitis) because the inflammation may be
exacerbated.

Ophthalmic bimatoprost, including DURYSTA® intracameral implant, has been
reported to cause changes to pigmented tissues, such as increased pigmentation
of the iris. Pigmentation of the iris is likely to be permanent. Patients who
receive treatment should be informed of the possibility of increased
pigmentation. While treatment with DURYSTA® can be continued in patients who
develop noticeably increased iris pigmentation, these patients should be
examined regularly.

Intraocular surgical procedures and injections have been associated with
endophthalmitis. Proper aseptic technique must always be used with administering
DURYSTA®, and patients should be monitored following the administration.


ADVERSE REACTIONS

In controlled studies, the most common ocular adverse reaction reported by 27%
of patients was conjunctival hyperemia. Other common adverse reactions reported
in 5%-10% of patients were foreign body sensation, eye pain, photophobia,
conjunctival hemorrhage, dry eye, eye irritation, intraocular pressure
increased, corneal endothelial cell loss, vision blurred, iritis, and headache.


INDICATIONS AND USAGE

DURYSTA® (bimatoprost intracameral implant) is indicated for the reduction of
intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular
hypertension (OHT).

Please see full Prescribing Information.

© 2022 AbbVie. All rights reserved.

All trademarks are the property of their respective owners.

US-DUR-210605   11/22

 * Terms of Use
 * Privacy Policy
 * contact us
 * about AbbVie
 * site map
 * Cookies Settings

Brought to you by



Study design for ARTEMIS Studies 1 and 2: Efficacy was evaluated in 2
multicenter, randomized, parallel-group, controlled, 20-month (including 8-month
extended follow-up) studies of DURYSTA® (bimatoprost intracameral implant)
compared to twice-daily topical timolol (0.5%) drops in patients with OAG or
OHT. IOP values obtained after initiation of non-study, IOP-lowering treatment
were excluded from the analysis.1,2

Primary efficacy endpoint: The study eye IOP at each hour was evaluated (Hours 0
and 2) at Weeks 2, 6, and 12.2

YOU ARE NOW LEAVING DURYSTAHCP.COM

PROCEED


PROCEED

*Effective for dates of service on or after October 1, 2020, bill as 10 units.

© 2020 Allergan. All rights reserved. All trademarks are
the property of their respective owners. DUR139462 08/20




×


AbbVie Inc. and Allergan plc are a new combined company. We will continue to
honor any Allergan-provided privacy notices for personal information previously
collected, used, and maintained by Allergan. Going forward, personal information
will be processed by this website according to AbbVie’s privacy notice
https://www.abbvie.com/privacy.html.

This site uses online tracking technologies such as cookies to personalize
content, save your preferences, provide social media features, enable
personalized advertising and track the site’s performance as described in our
Privacy Notice. Please click on Cookies Settings below to manage your
preferences.


Cookies Settings



PRIVACY PREFERENCE CENTER

When you visit any website, it may store or retrieve information on your
browser, mostly in the form of cookies. This information might be about you,
your preferences or your device and is mostly used to make the site work as you
expect it to. The information does not usually directly identify you, but it can
give you a more personalized web experience.

You can choose not to allow some types of cookies. Click on the different
category headings to find out more and change our default settings. However,
blocking some types of cookies may impact your experience of the site and the
services we are able to offer.
More information


MANAGE CONSENT PREFERENCES

REQUIRED COOKIES

Always Active

These cookies are necessary for the website to function and cannot be switched
off in our systems. They may be set by us or by third party providers whose
services we have added to our pages. They are usually only set in response to
actions made by you which amount to a request for services, such as setting your
privacy preferences, logging in or filling in forms. You can set your browser to
block or alert you about these cookies, but some parts of the site will not then
work.

FUNCTIONAL COOKIES

Always Active

These cookies allow us to count visits and traffic sources so we can measure and
improve the performance of our site. They may be set by us or by third party
providers whose services we have added to our pages. They help us to know which
pages are the most and least popular and see how visitors move around the site.

ADVERTISING COOKIES

Advertising Cookies

These cookies may be set through our site by our advertising partners to build a
profile of your interests and show you relevant adverts on other sites. They do
not store directly personal information but are based on uniquely identifying
your browser and internet device. If you do not allow these cookies, you will
experience less targeted advertising, but you will still receive online
advertising.

Back Button


PERFORMANCE COOKIES



Search Icon
Filter Icon

Clear
checkbox label label
Apply Cancel
Consent Leg.Interest
checkbox label label
checkbox label label
checkbox label label

Confirm My Choices